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Background: Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9
(PCSK9) under investigation for treatment of hypercholesterolemia and reduction of cardiovascular events.
Methods/design: The COMBO studies, part of the Phase 3 ODYSSEY clinical trial program, are designed to evaluate
the efficacy and safety of alirocumab as add-on therapy to stable, maximally tolerated daily statin, with or without
other lipid-lowering therapy (LLT), in a planned 966 patients with hypercholesterolemia at high cardiovascular risk.
COMBO I (http://clinicaltrials.gov/show/NCT01644175) is placebo-controlled, with a double-blind treatment period
of 52 weeks, and 306 planned patients who may receive other LLTs in addition to statin therapy. COMBO II
(http://clinicaltrials.gov/show/NCT01644188) has a double-blind treatment period of 104 weeks, comparing alirocumab
with ezetimibe in 660 planned patients receiving statin therapy (but no other LLTs). The primary efficacy endpoint is
the difference between treatment arms in percent change in low-density lipoprotein cholesterol (LDL-C) from baseline
to week 24. Both studies utilized a starting dose of alirocumab 75 mg every 2 weeks (Q2W; administered as 1 mL
solution via auto-injector). Patients with LDL-C levels ≥70 mg/dL after 8 weeks of treatment were up-titrated in a
blinded manner at week 12 to alirocumab 150 mg Q2W (also 1 mL auto-injector).
Discussion: In conclusion, the COMBO studies will provide information on the long-term efficacy and safety of
alirocumab in high-risk patients when administered in addition to maximally tolerated statin therapy, with a flexible
dosing strategy which allows for individualized therapy based on the degree of LDL-C lowering needed to achieve the
desired treatment response.
Trial registrations: COMBO I: NCT01644175 (http://clinicaltrials.gov/show/NCT01644175). COMBO II: NCT01644188
(http://clinicaltrials.gov/show/NCT01644188).
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The benefits of lowering low-density lipoprotein choles-
terol (LDL-C) levels on cardiovascular risk reduction for
patients with and without coronary heart disease (CHD)
are well established. For example, the 2012 Cholesterol
Treatment Trialists’ meta-analysis (n = 174,149), includ-
ing 22 controlled trials of standard statin regimens and
five trials comparing more intensive versus less inten-
sive statin regimens, showed a 21% reduction in cardio-
vascular disease (CVD) mortality and morbidity for
every ~40 mg/dL (1 mmol/L) reduction in LDL-C,
largely irrespective of age, sex, baseline LDL-C, or pre-
vious vascular disease [1]. The Cholesterol Treatment
Trialists’ Collaboration also showed that there is further
benefit from more intensive LDL-C lowering with statin
therapy, even if LDL-C is already lower than ~80 mg/dL
(2 mmol/L) at baseline [2].
European guidelines recommend LDL-C targets for
patients based on their cardiovascular risk [3,4]. In pa-
tients at very high risk, these guidelines recommend a
LDL-C goal of ~70 mg/dL (<1.8 mmol/L) [3,4], advocat-
ing a ≥50% reduction when target levels cannot be
reached [3]. For intermediate- and high-risk patients,
Canadian dyslipidemia guidelines recommend either a
LDL-C level of ~77 mg/dL (≤2.0 mmol/L) or at least a
50% reduction in LDL-C [5]. The recently published
2013 American College of Cardiology (ACC)/American
Heart Association (AHA) cholesterol management guide-
lines focus on intensity of statin treatment and recom-
mend either high- or moderate-intensity statin therapy
depending on cardiovascular risk [6]. High-intensity sta-
tin therapy (atorvastatin 40–80 mg/day or rosuvastatin
20–40 mg/day) generally reduces LDL-C levels by ≥50%
while moderate-intensity statin therapy reduces LDL-
by ≥30% to <50%. However, high-intensity statin ther-
apy may be insufficient to achieve LDL-C targets when
utilizing a ‘treat-to–target’ approach, may not be toler-
ated, or may be associated with a higher risk of myop-
athy [7]. Furthermore, despite the availability of other
lipid-lowering therapies (LLTs) including cholesterol ab-
sorption inhibitors (ezetimibe), many high-risk patients
with hypercholesterolemia still do not achieve adequate
control of LDL-C levels and experience cardiovascular
events [8-13]. Thus, treatment with other LDL-C-
lowering therapies (either in combination with or with-
out statin therapy) may be warranted to achieve better
LDL-C control. Indeed, the 2013 ACC/AHA guideline
recommends consideration of non-statin drug therapy
for high-risk individuals needing additional LDL-C low-
ering, such as those with clinical atherosclerotic CVD,
untreated LDL-C ≥190 mg/dL, or diabetes aged 40–75
years [6]. However, it should be noted that, to date,
major trials of these hypolipidemic drugs in combin-
ation with statins have failed to show any additionalimprovement in cardiovascular outcomes as compared
with statins alone [14,15].
Proprotein convertase subtilisin kexin type 9 (PCSK9)
is the ninth member of the proprotein convertase family
[16]. PCSK9 inhibitors protect hepatic LDLRs against
PCSK9-mediated degradation and, consequently, reduce
plasma levels of LDL-C [17]. PCSK9 inhibition has the
potential to provide a complementary mechanism to sig-
nificantly reduce LDL-C beyond what is possible with
statins, since statins are known to increase PCSK9 levels
at transcriptional level [18]. Several approaches to PCSK9
inhibition are in development, the most advanced being
monoclonal antibodies (mAbs), which prevent PCSK9
from binding to the LDLR (reviewed in Farnier, [19] and
Cariou et al. [20]).
Alirocumab is a fully human mAb to PCSK9 that has
shown considerable promise in Phase 2 trials [21-23] and
is currently in Phase 3 trials for the treatment of hyper-
cholesterolemia and reduction of cardiovascular events.
The COMBO I (http://clinicaltrials.gov/show/NCT0164
4175) and II (http://clinicaltrials.gov/show/NCT01644188)
trials form part of the alirocumab Phase 3 ODYSSEY clin-
ical trial program, which currently comprises 14 studies
across a range of patient groups and clinical settings in-
volving more than 23,500 planned patients, to further
assess the efficacy and safety of alirocumab. The COMBO
studies have been specifically designed to evaluate the
long-term efficacy and safety of alirocumab as add-on
therapy to stable, maximally tolerated, daily statin therapy
in patients with hypercholesterolemia at high cardiovascu-
lar risk. COMBO I compares alirocumab against placebo,
with patients permitted to receive other stable doses of
LLTs in addition to maximally tolerated daily statin ther-
apy. COMBO II compares alirocumab versus ezetimibe
when administered in conjunction with statin therapy only
(i.e. other LLTs are not allowed in COMBO II).
Methods
Study design
COMBO I is a Phase 3, randomized, double-blind, placebo-
controlled, parallel-group, multicenter, 52-week study being
conducted at 76 sites in the USA. This study evaluates
the efficacy and safety of alirocumab as add-on therapy
to stable, maximally tolerated doses of daily statin, with
or without other stable LLT, in a planned population of
306 high-risk patients with poorly controlled hypercholes-
terolemia (Figure 1A). COMBO I began screening patients
in July 2012 and completed collection of data in April
2014 (http://clinicaltrials.gov/show/NCT01644175); data
analyses are ongoing.
COMBO II is a Phase 3, randomized, double-blind,
active-controlled, parallel-group, multinational 104-week
study being conducted at 126 sites in Europe, Israel,
North America, South Africa, and South Korea. The
Figure 1 Study design. A) ODYSSEY COMBO I. B) ODYSSEY COMBO II. LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy;
NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III; PO, per os; Q2W, every 2 weeks; R, randomization; SC, subcutaneous;
TLC, therapeutic lifestyle changes.
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poorly controlled hypercholesterolemia on stable, max-
imally tolerated daily statin therapy. This study began
screening patients in August 2012 and is anticipated to
complete in July 2015 (http://clinicaltrials.gov/show/
NCT01644188). Unlike COMBO I, with a placebo arm,
COMBO II incorporates an active-treatment arm (ezeti-
mibe) with double-dummy design (Figure 1b) and pa-
tients are not allowed to receive any other LLTs besides
statin and their randomized treatment.
The studies are being conducted in compliance with
the principles laid down by the 18th World Medical As-
sembly (Helsinki, 1964) and all applicable amendments
laid down by the World Medical Assemblies and accord-
ing to the International Conference on Harmonization
Guidelines for Good Clinical Practice. The protocols havebeen reviewed and approved by the institutional review
board of each participating center (Additional file 1). All
participants have provided written informed consent.
Inclusion and exclusion criteria
Principal inclusion and exclusion criteria are shown in
Table 1; full inclusion and exclusion criteria for both
studies can be found in Additional file 1.
All patients in COMBO I and II have hypercholester-
olemia and established CHD or CHD risk equivalents,
with LDL-C poorly controlled with a maximally toler-
ated daily dose of statin. In COMBO I only, patients
were also permitted to receive other LLT on top of sta-
tin, provided both the statin and other LLT were at
stable dose for at least 4 weeks (6 weeks for fenofibrate)
prior to the screening visit; in COMBO II, statin dose
Table 1 Key inclusion and exclusion criteria*
Inclusion criteria†
COMBO I COMBO II
Patients with hypercholesterolemia and established CHD or CHD risk
equivalents# with LDL-C poorly controlled with a maximally tolerated
daily dose of statin with or without other LLT, both at stable dose
for at least 4 weeks (6 weeks for fenofibrate) prior to the screening
visit (week −2)
Patients with hypercholesterolemia and established CHD or CHD risk
equivalents# with LDL-C poorly controlled with a maximally tolerated
daily dose of statin at stable dose for at least 4 weeks prior to the
screening visit (week −3)
Baseline entry criteria: LDL-C levels depending on history of documented
CVD:
Baseline entry criteria: LDL-C levels depending on history of documented CVD:
• LDL-C ≥70 mg/dL (≥1.81 mmol/L) at the screening visit with a history
of documented CVD
• LDL-C ≥70 mg/dL (≥1.81 mmol/L) at the screening visit with a history
of documented CVD
• LDL-C ≥100 mg/dL (≥2.59 mmol/L) at the screening visit in patients
without history of documented CVD
• LDL-C ≥100 mg/dL (≥2.59 mmol/L) at the screening visit in patients
without history of documented CVD
Exclusion criteria†
COMBO I COMBO II
Age <18 years Age <18 years
Fasting serum triglycerides >400 mg/dL (>4.52 mmol/L) during the
screening period
Fasting serum triglycerides >400 mg/dL (>4.52 mmol/L) during the
screening period
Currently taking a statin that is not simvastatin, atorvastatin, or
rosuvastatin taken daily at a registered dose
Currently taking a statin that is not simvastatin, atorvastatin, or rosuvastatin
taken daily at a registered dose
Use of fibrates, other than fenofibrate, within 6 weeks prior to the
screening visit (week −2)
Use of concomitant meds
• Ezetimibe, omega-3 fatty acid (at doses ≥1,000 mg daily), nicotinic
acid, bile acid-binding sequestrant, or red yeast rice products in
the past 4 weeks prior to screening visit (week −3)
• Use of fibrates in the past 6 weeks prior to screening visit (week −3)
CHD, coronary heart disease; CVD, cardiovascular disease (defined as CHD, ischemic stroke or peripheral arterial disease – see Additional file 1 for additional
details); LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy.
*Further information on the inclusion and exclusion criteria can be found in Additional file 1.
†Differences between COMBO I and COMBO II are shown in bold font.
#See Additional file 1 for definition of CHD risk equivalents.
Colhoun et al. BMC Cardiovascular Disorders 2014, 14:121 Page 4 of 10
http://www.biomedcentral.com/1471-2261/14/121was required to be stable for at least 4 weeks prior to
the screening visit and other LLTs were not permitted.
At screening, patients either had LDL-C ≥70 mg/dL
(≥1.81 mmol/L) with documented CVD or LDL-
C ≥100 mg/dL (≥2.59 mmol/L) with no documented his-
tory of CVD (Table 1).
The ‘maximum tolerated dose’ of statin was defined as
either rosuvastatin 20 mg or 40 mg daily, atorvastatin
40 mg or 80 mg daily, or simvastatin 80 mg daily (if
already on this dose for >1 year). However, patients not
able to tolerate the above statin doses remained eligible
for inclusion if they were on a lower dose of daily ator-
vastatin, rosuvastatin, or simvastatin provided that the
investigator had a documented reason for not using the
higher dose (Additional file 1).
Study procedures
Patients meeting the inclusion criteria entered a screen-
ing period of up to 2 (COMBO I) or 3 (COMBO II)
weeks prior to randomization. During screening, pa-
tients completed informed consent, inclusion/exclusion
criteria were further assessed, patient information was
collected, and patients were trained in the use of the
auto-injector device. In addition, vital signs were taken,a 12-lead electrocardiogram was performed, and fasting
blood and urine samples were obtained for analysis. AEs
will be assessed from the screening visit throughout
the study.
LDL-C will be calculated using the Friedewald formula
at screening and at all time points during the double-
blind treatment periods. If TGs exceed 400 mg/dL
(4.52 mmol/L) then the central laboratory will reflexively
measure LDL-C (via the beta quantification method) ra-
ther than calculating it. LDL-C will also be measured
(via the beta quantification method) at week 0 and week
24. Other lipid parameters, including total cholesterol,
HDL-C, TGs, Apo B, Apo A1, and Lp(a), will be mea-
sured directly by the central laboratory.
COMBO I
Eligible patients were randomized (2:1 alirocumab:pla-
cebo), with stratification by 1) prior history of myocar-
dial infarction (MI) or ischemic stroke, and 2) intensity
of statin treatment, to ensure balance between arms for
these factors. After randomization, patients entered a
double-blind treatment period of 52 weeks. In addition
to existing statin and other existing LLT if appropriate,
patients randomized to alirocumab received a 75 mg
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tered as a single 1 mL injection utilizing an auto-injector,
from randomization to week 12. Patients randomized to
placebo received a 1 mL SC placebo injection from an
identical auto-injector.
At week 12, patients randomized to alirocumab were
up-titrated to 150 mg Q2W if the week 8 LDL-C
was ≥70 mg/dL (1.81 mmol/L). To maintain blinding, the
patient and investigator were not informed of the week 8
LDL-C levels (or any lipid values after randomization);
continuation or up-titration of dose occurred in an auto-
mated and blinded manner. The 150 mg Q2W dose of
alirocumab was also administered as a 1 mL solution in an
auto-injector.
On-site patient assessments during the treatment
period were scheduled at randomization and then weeks
4, 8, 12, 16, 24, 36, and 52 (end of treatment visit)
(Figure 1). After the treatment period, there will be an
8-week follow-up period.
COMBO II
Eligible patients were randomized (2:1 alirocumab:ezeti-
mibe), with stratification for 1) prior history of MI or is-
chemic stroke, 2) intensity of statin treatment, and
3) geographic region, to ensure balance between arms in
these factors. After randomization, patients entered a
double-blind, double-dummy treatment period of
104 weeks. Patients were randomized to either alirocu-
mab 75 mg SC Q2W plus placebo for ezetimibe per os
(PO) daily or placebo for alirocumab SC Q2W plus eze-
timibe 10 mg PO daily. At week 12, patients random-
ized to alirocumab were up-titrated to 150 mg Q2W if
the week 8 LDL-C was ≥70 mg/dL (1.81 mmol/L).
On-site patient assessments were scheduled at regular
intervals from randomization to week 104 (end of treat-
ment visit) (Figure 1). After the treatment period, there
will be an 8-week follow-up period.
In both studies, patients were asked to remain on a
stable diet (National Cholesterol Education Program
Adult Treatment Panel III therapeutic lifestyle changes
diet or equivalent) and the daily statin dose should be
stable throughout the entire study duration from screen-
ing to the follow-up visit. Modification to the statin
(and, in the case of COMBO I, other background LLT)
is only allowed under special circumstances.
Endpoints and assessments
The primary objective of both studies is to demonstrate
reduction of calculated LDL-C by alirocumab as add-on
therapy to stable maximally tolerated daily statin, either
(a) with or without other LLTs, in comparison with pla-
cebo (COMBO I) or (b) in comparison with ezetimibe
10 mg daily (COMBO II). The primary endpoint for
both studies is the difference between arms in percentchange in calculated LDL-C from baseline to week 24,
using all LDL-C values regardless of adherence to treat-
ment (intent-to-treat [ITT] approach). The key second-
ary efficacy endpoints are very similar in the two studies
and are summarized in Table 2.
Safety will be assessed throughout the duration of
the treatment periods by AE reporting (including adjudi-
cated cardiovascular events), laboratory analyses, and
vital signs measurement. Since the long-term effects of
PCSK9 inhibition on top of a statin in humans are un-
known, a number of AEs are defined as being of special
interest and will be monitored (Additional file 1).
Statistical analyses
Sample size determination
In COMBO I, a sample size of 45 patients (30 in alirocu-
mab, 15 in placebo) was determined to have 95% power to
detect a difference in mean percentage change in LDL-C
of 30% with a 0.05 two-sided significance level, assuming a
common standard deviation of 25% and all 45 patients
having an evaluable primary endpoint. Meanwhile, in
COMBO II, a sample size of 96 patients (64 in alirocumab,
32 in ezetimibe) was determined to have 95% power to de-
tect a difference in mean percentage change in LDL-C of
20% with a 0.05 two-sided significance level, assuming
common standard deviation of 25% and all 96 patients
having an evaluable primary endpoint.
However, to meet regulatory requirements across the
overall ODYSSEY Program, sample sizes were increased
in most of the alirocumab Phase 3 studies to assess the
safety of alirocumab appropriately in the overall integrated
safety database. Therefore, the final total sample sizes were
increased to 306 patients in COMBO I and 660 in
COMBO II, both with a randomization ratio of 2:1.
Primary analysis
The primary efficacy analysis population will be the ITT
population, comprising all randomized patients with at
least one baseline calculated LDL-C value available and
at least one calculated LDL-C value available at one of
the planned time points from weeks 4 to 24 (regardless
of treatment adherence).
The percentage change in calculated LDL-C from
baseline to week 24 will be analyzed using a mixed effect
model with repeated measures (MMRM) approach to
account for missing data [24,25]. All available post-
baseline data at planned time points from week 4 to 52
regardless of status on- or off-treatment will be used in
the MMRM for the ITT analysis, with the model used to
provide least-squares means estimates and comparison
between treatment arms of LDL-C reductions at week
24. The models will include fixed categorical effects
of treatment group, randomization strata, time point,
treatment-by-time point interaction, and strata-by-time
Table 2 Primary and key secondary endpoints in COMBO I and II
Primary endpoint Population
Percentage change in calculated LDL-C from baseline to week 24 in the ITT population, using all LDL-C values
regardless of adherence to treatment (ITT analysis)
ITT
Key secondary endpoints Population
Percentage change in calculated LDL-C from baseline to week 24 in the modified ITT population, using all LDL-C
values during the efficacy treatment period (on-treatment analysis)
mITT
Percentage change in calculated LDL-C from baseline to week 12 (ITT analysis) ITT
Percentage change in calculated LDL-C from baseline to week 12 (on-treatment analysis) mITT
Percentage change in Apo B from baseline to week 24 (ITT analysis) ITT
Percentage change in Apo B from baseline to week 24 (on-treatment analysis) mITT
Percentage change in non-HDL-C from baseline to week 24 (ITT analysis) ITT
Percentage change in non-HDL-C from baseline to week 24 (on-treatment analysis) mITT
Percentage change in total cholesterol from baseline to week 24 (ITT analysis) ITT
Percentage change in Apo B from baseline to week 12 (ITT analysis) ITT
Percentage change in non-HDL-C from baseline to week 12 (ITT analysis) ITT
Percentage change in total cholesterol from baseline to week 12 (ITT analysis) ITT
Percentage change in calculated LDL-C from baseline to week 52 (ITT analysis) ITT
Proportion of patients reaching calculated LDL-C <70 mg/dL (1.81 mmol/L) at week 24 (ITT analysis) ITT
Proportion of patients reaching calculated LDL-C <70 mg/dL (1.81 mmol/L) at week 24 (on-treatment analysis) mITT
Percentage change in Lp(a) from baseline to week 24 (ITT analysis) ITT
Percentage change in HDL-C from baseline to week 24 (ITT analysis) ITT
Percentage change in fasting TGs from baseline to week 24 (ITT analysis) ITT
Percentage change in Apo A1 from baseline to week 24 (ITT analysis) ITT
Percentage change in Lp(a) from baseline to week 12 (ITT analysis) ITT
Percentage change in HDL-C from baseline to week 12 (ITT analysis) ITT
Percentage change in fasting TGs from baseline to week 12 (ITT analysis) ITT
Percentage change in Apo A1 from baseline to week 12 (ITT analysis) ITT
Apo, apolipoprotein; HDL-C, high-density lipoprotein cholesterol; ITT, intent-to-treat; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); mITT modified
intent-to-treat; TGs, triglycerides.
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ates of baseline LDL-C value and baseline value-by-time
point interaction. Although both trials have the LDL-C
differences at week 24 as the primary endpoint, they ex-
tend beyond 24 weeks so as to maximize available safety
data and to generate further data on durability of lipid
lowering effects. The studies will extend to the planned
duration regardless of any efficacy data from the week
24 timepoint.
Secondary analysis
A hierarchical procedure will be used to control type I
error and handle multiple secondary endpoint analyses.
If the primary endpoint analysis (ITT) is significant at
5% alpha level, key secondary efficacy endpoints will be
tested sequentially in the order given in Table 2. In par-
ticular, LDL-C reduction at week 24 will be analyzed
‘on-treatment’ in the modified ITT (mITT) population if
the primary analysis is significant in the ITT population.The mITT population will exclude those patients from
the ITT population who do not have a calculated LDL-C
value available while on-treatment (defined as the period
between first dose of study treatment and up to 21 days
after last injection, or 3 days after last capsule intake,
whichever came first). For the on-treatment analysis, all
available on-treatment measurements (i.e. up to 21 days
after last injection/3 days after last capsule, whichever
comes first) at planned time points from weeks 4 to 52
will be used in the MMRM.
Continuous secondary endpoints, except Lp(a) and
TGs, will be analyzed using the same MMRM model as
for the primary endpoint. Lp(a) and TGs (which have a
non-Gaussian distribution) and the binary secondary
endpoints (proportion of patients with LDL-C <70 mg/
dL and <100 mg/dL) will be analyzed using a multiple
imputation approach for handling of missing values
followed by robust regression (for Lp[a] and TGs) or lo-
gistic regression (for the binary endpoints).
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AEs (including adjudicated cardiovascular events), la-
boratory parameters, and vital signs will be reported
descriptively, based on the safety population (all ran-
domized patients who received at least one dose or par-
tial dose of study treatment). The safety analysis will
focus on the treatment-emergent AE period, defined as
the time from the first double-blind dose to the last
double-blind dose of the investigational product + 70 days
(10 weeks). The studies are not powered to assess the im-
pact on cardiovascular outcomes, which will be assessed
in a separate, large outcomes study (http://clinicaltrials.
gov/show/NCT01663402) [26].
Discussion
Prior clinical studies and observational analyses have
demonstrated that many patients may struggle to
achieve effective control of their LDL-C levels utilizing
existing LLTs, with high baseline LDL-C levels, efficacy
limitations, intolerance, and poor compliance all contrib-
uting factors [27-32]. However, the addition of a mAb
targeting PCSK9 to existing LLT may help those patients
at high cardiovascular risk to achieve the recommended
LDL-C levels or percentage lowering. The ODYSSEY
COMBO studies are designed to assess the efficacy and
safety of alirocumab as add-on therapy to stable, max-
imally tolerated daily statin therapy in patients with
hypercholesterolemia at high cardiovascular risk versus
placebo (COMBO I) or ezetimibe (COMBO II). These
patients, at high cardiovascular risk, are recommended
for intensive lowering of LDL-C.
COMBO II will also allow a comparison of the efficacy
and safety of alirocumab versus ezetimibe, both given on
top of maximally tolerated doses of statin. Ezetimibe is
frequently added to statins to provide greater reductions
in LDL-C, particularly where patients are unable to tol-
erate titration to a higher potency [33]. However, while
generally well tolerated, ezetimibe lowers LDL-C levels
only modestly. As an add-on to statin therapy, a 15.1%
greater reduction in LDL-C was observed with statin +
ezetimibe combination therapy when compared with sta-
tin monotherapy in a meta-analysis of 27 double-blind,
placebo-controlled, or active comparative studies of over
21,000 subjects with a mean treatment duration of
9 weeks [34]. In this meta-analysis, only 10.3% of
patients with established CHD who received statin
monotherapy achieved the pre-defined LDL-C goal
of <70 mg/dL. Even with the addition of ezetimibe, only
32.1% of patients achieved this LDL-C goal, suggesting
the need for more effective LLT [34].
The trials within the ODYSSEY program use a treat-
to-goal approach and are designed to address unmet
needs of patient populations on current standard of care
unable to achieve LDL-C goals, using a flexible dosingstrategy for individualized therapy based on degree of
LDL-lowering needed to achieve an adequate treatment
response. A key aspect of the COMBO studies is the po-
tential to up-titrate alirocumab-treated patients based on
their LDL-C levels after 8 weeks of treatment. The start-
ing dose of 75 mg Q2W was selected to provide an ap-
proximate 50% decrease in LDL-C from baseline when
added to statin therapy, as determined by a dose-
response model [35]. As such, all patients were initially
treated with 75 mg Q2W. However, those patients
whose LDL-C levels remain ≥70 mg/dL after 8 weeks of
treatment were dose up-titrated in a blinded manner at
week 12 to 150 mg Q2W without a need to increase the
injection volume. With this flexible treatment scheme,
most patients can be expected to achieve an LDL-C level
of <70 mg/dL without reaching very low LDL-C levels.
However, there is the potential that some patients may
achieve LDL-C levels of below 25 mg/dL and reducing
LDL-C to such very low levels has been controversial
with respect to cancers and hemorrhagic stroke risks.
Several observational studies have suggested an associ-
ation between hemorrhagic stroke and low serum chol-
esterol [36-38]. Consistent with this, the Cholesterol
Treatment Trialists' meta-analysis [2] found an excess of
hemorrhagic stroke in the meta analysis of more versus
less intensive statin regimes, though the excess risk was
50 times less than the beneficial effect on occlusive
stroke. No association was found between intensive sta-
tin therapy and cancer risk [2]. Nonetheless, since data
from patients achieving very low levels of LDL-C are
sparse, additional monitoring by the Data Monitoring
Committee will be implemented for those patients
reaching LDL-C levels of <25 mg/dL to further evaluate
the safety of very low LDL-C levels.
The COMBO trials have used differing lipid entry cri-
teria depending on whether entrants had a clinical his-
tory of CVD or were CHD risk equivalent. This reflected
that at the time of design, the revised ATPIII then oper-
ant in the US did not include an unequivocal recom-
mendation of a target <70 mg/dL in all such patients,
but left it as a “therapeutic option” reflecting some de-
gree of uncertainty [39]. The new 2013 ACC/AHA
guidelines have moved away from citing lipid targets but
instead focus on the intensity of statin therapy being tai-
lored to CVD risk [6]. Most of the entrants to the
COMBO trials would be eligible for intensive therapy
under these new guidelines. Regardless of whether physi-
cians are working to these 2013 ACC/AHA guidelines
[6] or guidelines that continue to use LDL-C targets
[40], the data the COMBO trial will provide on the effi-
cacy and safety of alirocumab in high-risk patients when
administered in addition to maximally tolerated statin
therapy will be useful since patients warranting intensive
statin therapy may not tolerate it.
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http://www.biomedcentral.com/1471-2261/14/121Overall, the ODYSSEY program comprises 14 studies
of more than 23,500 planned subjects across more than
2,000 study centers worldwide. The program will evalu-
ate multiple patient populations (including patients at
high cardiovascular risk, patients with heterozygous
familial hypercholesterolemia, and patients with well-
defined statin intolerance) and different treatment op-
tions (including alirocumab monotherapy, combination
therapy with statins and other LLTs, and flexible dosing
options). These studies follow a robust approach to in-
vestigate a new class of drugs with a novel mechanism
of action, with efficacy and safety studies ranging from
24–104 weeks duration (rather than 12–52 weeks) to
provide a greater amount of double-blind safety data for
building confidence in alirocumab as a potential thera-
peutic option. Of note, the ODYSSEY program also in-
cludes a large cardiovascular outcomes study (http://
clinicaltrials.gov/show/NCT01663402) [26] which will
determine the long-term impact of alirocumab and
lower levels of LDL-C on the occurrence of cardiovascu-
lar events in 18,000 patients after a recent (<52 weeks)
acute coronary syndrome event, with a randomized
treatment period of 64 months.
In summary, the COMBO studies are the longest dur-
ation placebo/ezetimibe-controlled trials of a PCSK9
inhibitor in high-risk patients with poorly controlled
LDL-C on maximum tolerated standard of care. They
will help to guide clinical decision making on the next
LLT to use beyond statin therapy.
Additional file
Additional file 1: Additional study details.
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